Point72 Asset Management L.P. Takes $1.84 Million Position in Genmab A/S (NASDAQ:GMAB)

Point72 Asset Management L.P. acquired a new position in Genmab A/S (NASDAQ:GMAB) during the fourth quarter, Holdings Channel reports. The institutional investor acquired 88,146 shares of the company’s stock, valued at approximately $1,840,000.

A number of other hedge funds and other institutional investors have also modified their holdings of GMAB. Point72 Hong Kong Ltd acquired a new position in shares of Genmab A/S during the fourth quarter valued at about $911,000. Quantinno Capital Management LP boosted its stake in Genmab A/S by 273.2% during the fourth quarter. Quantinno Capital Management LP now owns 90,335 shares of the company’s stock worth $1,885,000 after buying an additional 66,128 shares in the last quarter. OMERS ADMINISTRATION Corp acquired a new stake in shares of Genmab A/S during the 4th quarter valued at about $378,000. Laird Norton Wetherby Wealth Management LLC raised its position in Genmab A/S by 17.3% in the fourth quarter. Laird Norton Wetherby Wealth Management LLC now owns 13,711 shares of the company’s stock worth $286,000 after purchasing an additional 2,023 shares in the last quarter. Finally, Hudson Bay Capital Management LP raised its position in Genmab A/S by 103.8% in the fourth quarter. Hudson Bay Capital Management LP now owns 540,000 shares of the company’s stock worth $11,270,000 after purchasing an additional 275,000 shares in the last quarter. Institutional investors own 7.07% of the company’s stock.

Genmab A/S Stock Performance

Shares of NASDAQ:GMAB opened at $20.52 on Thursday. The business has a fifty day moving average of $19.75 and a 200-day moving average of $20.72. Genmab A/S has a twelve month low of $17.24 and a twelve month high of $30.06. The firm has a market cap of $13.16 billion, a PE ratio of 11.79, a price-to-earnings-growth ratio of 2.65 and a beta of 1.04.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.31 EPS for the quarter, topping analysts’ consensus estimates of $0.23 by $0.08. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. The firm had revenue of $715.00 million for the quarter, compared to analyst estimates of $5.17 billion. On average, analysts anticipate that Genmab A/S will post 1.45 EPS for the current fiscal year.

Analysts Set New Price Targets

GMAB has been the topic of a number of recent research reports. Leerink Partnrs raised Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Thursday, February 13th. William Blair raised Genmab A/S from a “market perform” rating to an “outperform” rating in a research note on Tuesday, March 11th. Leerink Partners upgraded Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price objective for the company in a research note on Thursday, February 13th. Sanford C. Bernstein cut Genmab A/S from a “market perform” rating to an “underperform” rating in a report on Tuesday, April 1st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $37.00 target price (down previously from $50.00) on shares of Genmab A/S in a report on Wednesday, April 9th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $39.17.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.